Piperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy

Palang Chotsiri, Julie R. Gutman, Rukhsana Ahmed, Jeanne Rini Poespoprodjo, Din Syafruddin, Carole Khairallah, Puji B.S. Asih, Anne L'lanziva, Kephas Otieno, Simon Kariuki, Peter Ouma, Vincent Were, Abraham Katana, Ric N. Price, Meghna Desai, Feiko O. ter Kuile, Joel Tarning

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)
49 Downloads (Pure)

Abstract

Dihydroartemisinin-piperaquine (DP) is a long-acting artemisinin combination treatment that provides effective chemoprevention and has been proposed as an alternative antimalarial drug for intermittent preventive therapy in pregnancy (IPTp). Several pharmacokinetic studies have shown that dose adjustment may not be needed for the treatment of malaria in pregnancy with DP. However, there are limited data on the optimal dosing for IPTp. This study aimed to evaluate the population pharmacokinetics of piperaquine given as IPTp in pregnant women. Pregnant women were enrolled in clinical trials conducted in Kenya and Indonesia and treated with standard 3-day courses of DP, administered in 4- to 8-week intervals from the second trimester until delivery. Pharmacokinetic blood samples were collected for piperaquine drug measurements before each treatment round, at the time of breakthrough symptomatic malaria, and at delivery. Piperaquine population pharmacokinetic properties were investigated using nonlinear mixed-effects modeling with a prior approach. In total, data from 366 Kenyan and 101 Indonesian women were analyzed. The pharmacokinetic properties of piperaquine were adequately described using a flexible transit absorption (n = 5) followed by a three-compartment disposition model. Gestational age did not affect the pharmacokinetic parameters of piperaquine. After three rounds of monthly IPTp, 9.45% (95% confidence interval [CI], 1.8 to 26.5%) of pregnant women had trough piperaquine concentrations below the suggested target concentration (10.3 ng/ml). Translational simulations suggest that providing the full treatment course of DP at monthly intervals provides sufficient protection to prevent malaria infection. Monthly administration of DP has the potential to offer optimal prevention of malaria during pregnancy.

Original languageEnglish
Article numbere01150-20
Pages (from-to)1-13
Number of pages13
JournalAntimicrobial Agents and Chemotherapy
Volume65
Issue number3
DOIs
Publication statusPublished - Mar 2021

Bibliographical note

Publisher Copyright:
© 2021 Chotsiri et al.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Fingerprint

Dive into the research topics of 'Piperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy'. Together they form a unique fingerprint.

Cite this